 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...26272829303132333435363738» |
- balixafortide (POL 6326) / Spexis
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 26, 2016
P1, N=48, Recruiting, Sponsor: Polyphor Ltd.
N=24 --> 48 | Trial primary completion date: Dec 2015 --> Dec 2016
- Halaven (eribulin mesylate) / Eisai
New P2 trial: ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer. (clinicaltrials.gov) - Feb 12, 2016
P2, N=12, Recruiting, Sponsor: Imperial College London
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Feb 10, 2016
P1/2, N=23, Completed, Sponsor: howard safran
N=24 --> 48 | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=63 --> 23
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, BRCA Biomarker, Patient reported outcomes, Metastases: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Jan 28, 2016
P2, N=90, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=63 --> 23 Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Jan 26, 2016
P3, N=310, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- ||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial initiation date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jan 26, 2016
P3, N=328, Not yet recruiting, Sponsor: Immunomedics, Inc.
Recruiting --> Active, not recruiting Initiation date: Dec 2016 --> Jul 2016
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Jan 21, 2016
P2, N=50, Completed, Sponsor: NSABP Foundation Inc
Initiation date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed
- |||||| Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jan 21, 2016
P3, N=370, Recruiting, Sponsor: Japan Breast Cancer Research Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Jan 20, 2016
P2, N=29, Active, not recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial initiation date, Trial primary completion date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jan 20, 2016
P3, N=328, Not yet recruiting, Sponsor: Immunomedics, Inc.
Recruiting --> Active, not recruiting Initiation date: Apr 2016 --> Dec 2016 | Trial primary completion date: Apr 2019 --> Dec 2019
- Kineret (anakinra) / SOBI
Trial primary completion date, Metastases, Immune cell: Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Jan 17, 2016
P1, N=20, Recruiting, Sponsor: Baylor Research Institute
Initiation date: Apr 2016 --> Dec 2016 | Trial primary completion date: Apr 2019 --> Dec 2019 Trial primary completion date: Dec 2015 --> Dec 2016
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=77, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Sep 2014
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=77, Completed, Sponsor: Eisai Limited
Trial primary completion date: Dec 2015 --> Sep 2014 Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Dec 29, 2015
P2, N=39, Not yet recruiting, Sponsor: Virginia G. Kaklamani
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Dec 25, 2015
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Aug 2007 --> Dec 2016
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Trial initiation date, Combination therapy: Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 22, 2015
P1, N=18, Recruiting, Sponsor: Tom Badgett
Trial primary completion date: Aug 2007 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015
- Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Dec 21, 2015
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015 Suspended --> Completed | Trial primary completion date: May 2016 --> Jun 2015
- | Halaven (eribulin mesylate) / Eisai
New P2 trial: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Dec 9, 2015
P2, N=25, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- Halaven (eribulin mesylate) / Eisai
New P1 trial, Combination therapy: Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers (clinicaltrials.gov) - Nov 30, 2015
P1, N=1, Recruiting, Sponsor: Istituti Ospitalieri di Cremona
- Halaven (eribulin mesylate) / Eisai
Enrollment open: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (clinicaltrials.gov) - Nov 27, 2015
P2, N=20, Recruiting, Sponsor: Case Comprehensive Cancer Center
Suspended --> Completed | Trial primary completion date: May 2016 --> Jun 2015 Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Nov 19, 2015
P1/2, N=145, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Aug 2007
- | Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy: A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Nov 5, 2015
P1/2, N=21, Recruiting, Sponsor: University of Colorado, Denver
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy, Metastases: Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination (clinicaltrials.gov) - Oct 27, 2015
P1, N=40, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Aug 2007 Active, not recruiting --> Completed
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - Oct 23, 2015
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
New P3 trial, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Oct 22, 2015
P3, N=328, Not yet recruiting, Sponsor: Immunomedics, Inc.
- Halaven (eribulin mesylate) / Eisai
New P2 trial: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (clinicaltrials.gov) - Oct 22, 2015
P2, N=20, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=29, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> May 2016
- |||| Onzeald (etirinotecan pegol) / Nektar Therap
Trial primary completion date, Metastases: The BEACON Study (Breast Cancer Outcomes With NKTR-102) (clinicaltrials.gov) - Sep 24, 2015
P3, N=840, Active, not recruiting, Sponsor: Nektar Therapeutics
Trial primary completion date: Nov 2015 --> May 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - Sep 21, 2015
P3, N=600, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Halaven (eribulin mesylate) / Eisai
New trial, Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=120, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Combination therapy, Metastases: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Sep 4, 2015
P1/2, N=95, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Dec 2014 --> Dec 2016 Not yet recruiting --> Recruiting
- |||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Sep 2, 2015
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021
- |||||| Margenza (margetuximab) / MacroGenics, ZAI Lab
Enrollment open, Metastases: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Sep 1, 2015
P3, N=530, Recruiting, Sponsor: MacroGenics
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021 Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai, stenoparib (2X-121) / Allarity Therap, Oncoheroes
Enrollment change, Trial withdrawal, Trial primary completion date: Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers (clinicaltrials.gov) - Aug 25, 2015
P1/2, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
Not yet recruiting --> Recruiting N=54 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2018 --> Apr 2015
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, BRCA Biomarker, Patient reported outcomes, Metastases: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Aug 24, 2015
P2, N=90, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=54 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2018 --> Apr 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: ESKIMO: Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Aug 21, 2015
P4, N=101, Active, not recruiting, Sponsor: Eisai Korea Inc.
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Jul 2016 --> Jul 2015
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: SAKK 25/14: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer (clinicaltrials.gov) - Aug 18, 2015
P2, N=77, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: Jul 2016 --> Jul 2015 Not yet recruiting --> Recruiting
- Kineret (anakinra) / SOBI
Trial primary completion date, Metastases, Immune cell: Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Aug 13, 2015
P1, N=20, Recruiting, Sponsor: Baylor Research Institute
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Dec 2015
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer (clinicaltrials.gov) - Aug 12, 2015
P2, N=7, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Jun 2015 --> Dec 2015 Recruiting --> Active, not recruiting | N=47 --> 7 | Trial primary completion date: Oct 2015 --> Apr 2016
- |||| Halaven (eribulin mesylate) / Eisai
Biomarker, Trial completion, IO biomarker: NeoEribulin: Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (clinicaltrials.gov) - Aug 12, 2015
P2, N=163, Completed, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting | N=47 --> 7 | Trial primary completion date: Oct 2015 --> Apr 2016 Recruiting --> Completed
- Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Enrollment open, Combination therapy, Metastases: PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2015
P2, N=138, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Perjeta (pertuzumab) / Roche
New P3 trial, Metastases: PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Aug 4, 2015
P3, N=370, Not yet recruiting, Sponsor: Japan Breast Cancer Research Group
- ||||| Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy, Metastases: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Jul 31, 2015
P1/2, N=95, Not yet recruiting, Sponsor: Eisai Inc.
- balixafortide (POL 6326) / Spexis
Trial primary completion date, Combination therapy, Metastases: Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 9, 2015
P1, N=24, Recruiting, Sponsor: Polyphor Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- |||||||||| Margenza (margetuximab) / MacroGenics, ZAI Lab
New P3 trial, Metastases: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=530, Not yet recruiting, Sponsor: MacroGenics
- Halaven (eribulin mesylate) / Eisai
Enrollment change: BOLD 113: This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (clinicaltrials.gov) - Jul 6, 2015
P1, N=20, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Dec 2014 --> Dec 2015 N=94 --> 20
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov) - Jul 2, 2015
P2, N=52, Active, not recruiting, Sponsor: Eisai Inc.
N=94 --> 20 Trial primary completion date: Jun 2015 --> Mar 2013
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed: Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer (clinicaltrials.gov) - Jul 2, 2015
P2, N=81, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2015 --> Mar 2013 Completed --> Active, not recruiting
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Combination therapy, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 29, 2015
P1, N=251, Recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jun 25, 2015
P2, N=58, Recruiting, Sponsor: Eisai Inc.